ATARA Biotherapeutics (NASDAQ: ATRA) reported Q1 EPS of ($0.72), $0.35 worse than the analyst estimate of ($0.37). Revenue for the quarter came in at $1.23 million versus the consensus estimate of $32.01 million.

For earnings history and earnings-related data on ATARA Biotherapeutics (ATRA) click here.